Download or read book Update on Hepatitis C written by Martina Smolic and published by BoD – Books on Demand. This book was released on 2017-10-04 with total page 240 pages. Available in PDF, EPUB and Kindle. Book excerpt: In the past few years, remarkable progress has been made in our understanding of HCV biology, pathogenesis of infection, and structure-function relationships. This has led to quantum advances in clinical efficacy and tolerability. Yet, in spite of this amazing progress, there remain obstacles to widespread successful treatment. These issues include biological failures even with direct-acting agents, lack of options for individual with organ failures, drug-drug interactions, access to medications either due to lack of availability or affordability, and psychiatric and social issues. These problems are likely to remain in the future. Therefore, this book has been created by distinguished faculties from around the world to address the progress in our understanding of HCV infection and to review new treatment options, limitations, and accessibility of new therapeutic options.

Download or read book Eliminating the Public Health Problem of Hepatitis B and C in the United States written by National Academies of Sciences, Engineering, and Medicine and published by National Academies Press. This book was released on 2016-06-01 with total page 187 pages. Available in PDF, EPUB and Kindle. Book excerpt: Hepatitis B and C cause most cases of hepatitis in the United States and the world. The two diseases account for about a million deaths a year and 78 percent of world's hepatocellular carcinoma and more than half of all fatal cirrhosis. In 2013 viral hepatitis, of which hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most common types, surpassed HIV and AIDS to become the seventh leading cause of death worldwide. The world now has the tools to prevent hepatitis B and cure hepatitis C. Perfect vaccination could eradicate HBV, but it would take two generations at least. In the meantime, there is no cure for the millions of people already infected. Conversely, there is no vaccine for HCV, but new direct-acting antivirals can cure 95 percent of chronic infections, though these drugs are unlikely to reach all chronically-infected people anytime soon. This report, the first of two, examines the feasibility of hepatitis B and C elimination in the United States and identifies critical success factors. The phase two report will outline a strategy for meeting the elimination goals discussed in this report.

Download or read book Guidelines on Hepatitis B and C Testing written by World Health Organization and published by World Health Organization. This book was released on 2017 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt: Testing and diagnosis of hepatitis B (HBV) and C (HCV) infection is the gateway for access to both prevention and treatment services, and is a crucial component of an effective response to the hepatitis epidemic. Early identification of persons with chronic HBV or HCV infection enables them to receive the necessary care and treatment to prevent or delay progression of liver disease. Testing also provides an opportunity to link people to interventions to reduce transmission, through counselling on risk behaviors and provision of prevention commodities (such as sterile needles and syringes) and hepatitis B vaccination. These are the first WHO guidelines on testing for chronic HBV and HCV infection and complement published guidance by WHO on the prevention, care and treatment of chronic hepatitis C and hepatitis B infection. These guidelines outline the public health approach to strengthening and expanding current testing practices for HBV and HCV, and are intended for use across age groups and populations.

Download or read book A National Strategy for the Elimination of Hepatitis B and C written by National Academies of Sciences, Engineering, and Medicine and published by National Academies Press. This book was released on 2017-06-30 with total page 297 pages. Available in PDF, EPUB and Kindle. Book excerpt: Hepatitis B and C cause most cases of hepatitis in the United States and the world. The two diseases account for about a million deaths a year and 78 percent of world's hepatocellular carcinoma and more than half of all fatal cirrhosis. In 2013 viral hepatitis, of which hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most common types, surpassed HIV and AIDS to become the seventh leading cause of death worldwide. The world now has the tools to prevent hepatitis B and cure hepatitis C. Perfect vaccination could eradicate HBV, but it would take two generations at least. In the meantime, there is no cure for the millions of people already infected. Conversely, there is no vaccine for HCV, but new direct-acting antivirals can cure 95 percent of chronic infections, though these drugs are unlikely to reach all chronically-infected people anytime soon. This report, the second of two, builds off the conclusions of the first report and outlines a strategy for hepatitis reduction over time and specific actions to achieve them.

Download or read book Hepatitis and Liver Cancer written by Institute of Medicine and published by National Academies Press. This book was released on 2010-05-23 with total page 252 pages. Available in PDF, EPUB and Kindle. Book excerpt: The global epidemic of hepatitis B and C is a serious public health problem. Hepatitis B and C are the major causes of chronic liver disease and liver cancer in the world. In the next 10 years, 150,000 people in the United States will die from liver disease or liver cancer associated with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections. Today, between 800,000 and 1.4 million people in the United States have chronic hepatitis B and between 2.7 and 3.9 million have chronic hepatitis C. People most at risk for hepatitis B and C often are the least likely to have access to medical services. Reducing the rates of illness and death associated with these diseases will require greater awareness and knowledge among health care workers, improved identification of at-risk people, and improved access to medical care. Hepatitis B is a vaccine-preventable disease. Although federal public health officials recommend that all newborns, children, and at-risk adults receive the vaccine, about 46,000 new acute cases of the HBV infection emerge each year, including 1,000 in infants who acquire the infection during birth from their HBV-positive mothers. Unfortunately, there is no vaccine for hepatitis C, which is transmitted by direct exposure to infectious blood. Hepatitis and Liver Cancer identifies missed opportunities related to the prevention and control of HBV and HCV infections. The book presents ways to reduce the numbers of new HBV and HCV infections and the morbidity and mortality related to chronic viral hepatitis. It identifies priorities for research, policy, and action geared toward federal, state, and local public health officials, stakeholder, and advocacy groups and professional organizations.

Download or read book Health Information for International Travel 2005 2006 written by Paul Arguin and published by . This book was released on 2005 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book Curing Hepatitis C written by Gregory T. Everson and published by Hatherleigh Press. This book was released on 2012-08-21 with total page 185 pages. Available in PDF, EPUB and Kindle. Book excerpt: Hepatitis C Doesn't Have to Be a Lifelong Illness Curing Hepatitis C provides the latest information to guide you through the diagnosis and treatment of hepatitis C. If you or a loved one has been diagnosed with hepatitis C, this book provides an indispensable and comprehensive overview of everything you need to know to take the right steps toward a cure. For the nearly 160 million people worldwide and 4 million Americans diagnosed with hepatitis C, there is now hope. Although hepatitis C was once considered incurable, medical and technological innovations have made a cure possible. A new frontier of treatment options has improved upon previous methods by curbing side-effects more effectively and working to eradicate hepatitis C entirely. Curing Hepatitis C also includes: * Easy-to-understand explanations of the nature of hepatitis C * The revealing truth of misconceptions about hepatitis C * Tips to prevent, diagnose, cope with, and ultimately cure this disease * An overview of types of tests and how to understand your results * Breakthrough treatments and medications for hepatitis C, such as triple therapy * The next generation of treatments including interferon-free regimens, QUAD therapy, host-acting antivirals, and more * Personal anecdotes from those affected by hepatitis C

Download or read book Free from Hepatitis C written by Lucinda K. Porter and published by Square One Publishers, Inc.. This book was released on 2012-04-19 with total page 227 pages. Available in PDF, EPUB and Kindle. Book excerpt: For decades, having hepatitis C virus (HCV) was the equivalent of serving a life sentence—with a dangerous liver disease. All of that changed with the discovery that the virus could be defeated with a new treatment. To shed light on this groundbreaking therapy, Lucinda Porter, a registered nurse, a passionate HCV advocate, and a hep C patient herself, has written a comprehensive guide for people who are undergoing or considering this new hep C treatment. Ms. Porter begins by explaining what hepatitis C is. She then looks at both the mainstream and the alternative management techniques currently used to keep the virus in check. From there, she examines hep C’s new therapy and what you can expect from it. The author demystifies test results, provides important questions you can ask your healthcare provider, and offers advice—all with the compassion of someone who has gone through the process herself. Well over 3 million North Americans live with hepatitis C. Here, at last, is all the information they need to make informed decisions about their future.

Download or read book Chronic Hepatitis C Virus written by Mitchell L. Shiffman and published by Springer Science & Business Media. This book was released on 2011-11-17 with total page 333 pages. Available in PDF, EPUB and Kindle. Book excerpt: Chronic Hepatitis C Virus: Lessons from the Past, Promise for the Future documents the monumental advances that have been made in our understanding of chronic HCV during the past decade. The first section reviews the natural history of chronic HCV, how this virus can affect other organs in addition to the liver, and whether treating chronic HCV alters the natural history of this disease. Section 2 reviews the advances that have been made in the treatment of chronic HCV during the past decade with interferon based therapy. Separate chapters on response guided therapy and how to manage the adverse events associated with these medications provide the physician with the concepts required to more effectively treat chronic HCV now and in the future. As the genetics of virologic response have recently been elucidated, a chapter is devoted to helping the clinician understand how genes that modulate disease processes and their treatment are identified and utilized in clinical care. Section 3 deals with the future of HCV treatment and specific inhibitors of HCV. Specific chapters explain how targets for drugs are identified and how drugs are then developed and tested; how mutations of HCV develop and how anti-viral agents will affect this process; the most up to date data regarding the treatment of chronic HCV with peginterferon, ribavirin and anti-viral agents; and the potential to treat chronic HCV with just oral anti-viral agents and without peginterferon and ribavirin in the future. The final section of this book covers issues related to liver transplantation in patients with chronic HCV. Separate chapters review the natural history of chronic HCV in liver transplant recipients and the impact of utilizing HCV positive donors. The volume concludes with chapters that cover the treatment of chronic HCV both prior to and after liver transplantation with potent anti-viral agents. Chronic Hepatitis C Virus: Lessons from the Past, Promise for the Future is a valuable resource for all physicians caring for patients with chronic HCV.

Download or read book Hepatitis C Virus From Molecular Virology to Antiviral Therapy written by Ralf Bartenschlager and published by Springer Science & Business Media. This book was released on 2013-03-12 with total page 353 pages. Available in PDF, EPUB and Kindle. Book excerpt: Hepatitis C virus (HCV), a major causative agent of chronic liver disease, is spread throughout the world and around 170 million people are persistently infected. In this volume, world-leading experts in the field of HCV research have compiled the most recent scientific advances to provide a comprehensive and very timely overview of the various facets of HCV. The book starts with a discussion of the possible origin of HCV and its spread among the human population. The focus of the subsequent chapters is on available cell culture and in vivo models before shifting to the molecular and cellular principles underlying the viral replication cycle. These chapters are complemented by insightful descriptions of the innate and adaptive immune responses to HCV as well as the virus-associated pathogenesis. Finally, the development of antiviral therapies, which is closely linked with progress in basic research, and the implementation of those therapies into present and future daily clinical practice are highlighted.

Download or read book Prevention of Progression in Chronic Liver Disease written by N. Hiyashi and published by Springer Science & Business Media. This book was released on 2004-07-21 with total page 140 pages. Available in PDF, EPUB and Kindle. Book excerpt: In several liver diseases, the underlying cause cannot always be eliminated, i.e. the progression of liver disease cannot be prevented. This is particularly true for non-responders to the treatment of chronic hepatitis C (HCV). It is relevant for more than 40% of patients with HCV genotype 1 and up to 20% of patients with genotype 2 or 3. Several approaches are now underway to prevent or ameliorate mechanisms of disease progression. In Asia, and particularly in Japan, Glycyrrhizine-SNMC has been widely used for this purpose. At present, SNMC is under clinical evaluation in Europe. This book, the proceedings of the Falk Workshop on 'Prevention of Progression in Chronic Liver Disease - An Update on SNMC (Stronger Neo-Minophagen C)' (Part IV of the XII Falk Liver Week, in honour of Hans Popper's 100th birthday) held in Freiburg, Germany, on 22 October 2003, is devoted to the understanding of basic mechanisms of fibrogenesis, the state of the art of non-invasive markers of disease progression that may substitute liver biopsy in the future, and of other predictive parameters indicating disease progression, in particular the development of hepatocellular carcinoma. All these problems are particularly relevant for chronic hepatitis C. A better characterization of so-called non-responders for the treatments available is crucial for the development of new strategies preventing or postponing disease progression. Such strategies should influence fibrogenesis and, thus, cirrhosis formation as well as the development of life threatening complications of liver cirrhosis, including hepatocellular carcinoma. In this volume, the available information on SNMC as an approach to prevent progression of chronic liver disease is discussed by several internationally renowned authors who report on the mechanisms of liver fibrogenesis and fibrolysis, on non-invasive markers of disease progression, and on hepatocellular carcinoma as one of the major complications of liver cirrhosis nowadays. Finally, experts from Japan report on their knowledge and experience concerning the drug SNMC/Glycyrrhizine in the prevention of cirrhosis and HCC, and first study results from Europe are presented.

Download or read book Non A Non B Hepatitis written by R. J. Gerety and published by . This book was released on 1981 with total page 328 pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book Hepatitis C Virus Update written by David R. Nelson and published by Saunders. This book was released on 2006-11 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt: No further information found for this title.

Download or read book Guidelines for the Prevention Care and Treatment of Persons with Chronic Hepatitis B Virus Infection written by WHO. and published by . This book was released on 2015 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt: These are the first World Health Organization (WHO) guidelines for theprevention care and treatment of persons living with CHB infection andcomplement similar recent published guidance by WHO on the prevention care and treatment of infection due to the hepatitis C virus (HCV). In contrastto several recent international guidelines on the management of CHB infectionfrom the United States Europe Asia-Pacific and the United Kingdom (UK) theprimary audience for these WHO guidelines is country programme managers inall settings but particularly in LMICs to help plan the development and scale up.

Download or read book The New Hepatitis C written by Nancy Reau and published by Oxford University Press. This book was released on 2018-02-23 with total page 240 pages. Available in PDF, EPUB and Kindle. Book excerpt: Fueled in part by the opioid epidemic, the number of reported hepatitis C virus infections tripled in the United States between 2010 and 2015. As new infections continue to mount, new therapies have produced seismic changes in how HCV is treated clinically, leaving a gap between the most current clinical guidance and the ongoing demands of patient care. The New Hepatitis C is a current and essential review of HCV's epidemiology, diagnosis, and clinical approaches -- a clinician's guidebook for navigating everything from screening to treatment. Acute and chronic HCV are addressed, as are important new treatment options for HCV, management of side effects, and a convenient summary of clinical trials on the treatment of chronic hepatitis C. Updated to detail the standards of care that will define the next decade of HCV management, this evidence-based volume is an essential clinical reference for to any practitioner in gastroenterology, hepatology, infectious disease, transplant, or internal medicine.

Download or read book Red Book Atlas of Pediatric Infectious Diseases written by American Academy of Pediatrics and published by . This book was released on 2007 with total page 440 pages. Available in PDF, EPUB and Kindle. Book excerpt: Based on key content from Red Book: 2006 Report of the Committee on Infectious Diseases, 27th Edition, the new Red Bookr Atlas is a useful quick reference tool for the clinical diagnosis and treatment of more than 75 of the most commonly seen pediatric infectious diseases. Includes more than 500 full-color images adjacent to concise diagnostic and treatment guidelines. Essential information on each condition is presented in the precise sequence needed in the clinical setting: Clinical manifestations, Etiology, Epidemiology, Incubation period, Diagnostic tests, Treatment

Download or read book Guidelines for the Screening Care and Treatment of Persons with Chronic Hepatitis C Infection Updated Version April 2016 written by World Health Organization and published by World Health Organization. This book was released on 2016-04-30 with total page 140 pages. Available in PDF, EPUB and Kindle. Book excerpt: The field of HCV therapeutics continues to evolve rapidly and since the World Health Organization (WHO) issued its first Guidelines for the screening care and treatment of persons with hepatitis C infection in 2014 several new medicines have been approved by at least one stringent regulatory authority. These medicines called direct-acting antivirals (DAAs) are transforming the treatment of HCV enabling regimens that can be administered orally are of shorter duration (as short as eight weeks) result in cure rates higher than 90% and are associated with fewer serious adverse events than the previous interfere on containing regimens. WHO is updating its hepatitis C treatment guidelines to provide recommendations for the use of these new medicines. The objectives of these WHO guidelines are to provide updated evidence-based recommendations for the treatment of persons with hepatitis C infection using where possible all DAA-only combinations. The guidelines also provide recommendations on the preferred regimens based on a patient?s HCV genotype and clinical history and assess the appropriateness of continued use of certain medicines. This document also includes existing recommendations on screening for HCV infection and care of persons infected with HCV that were first issued in 2014. The key audience for these guidelines are policy-makers in low- and middle-income countries who formulate country-specific treatment guidelines and who plan infectious disease treatment programmes and services in addition to those people responsible for delivering treatment. The guidelines are appropriate for all countries including high-income countries.